A review article summarizes the results of the randomised clinical trials which studied the efficacy and safety of simeprevir plus sofosbuvir with or without ribavirin in patients with chronic infection with HCV genotype 1. An addition of ribavirin did not improve the efficacy of combination therapy. In non-cirrhotic patients with HCV infection, the antiviral treatment with simeprevir and sofosbuvir can be continued for 12 weeks. In patients with compensated liver cirrhosis, 12week treatment with two antiviral agents is possible in the presence of favorable predictors of sustained virological response, e.g. serum albumin >40 g/L, platelet count >90 × 109/L, hepatic elasticity <20 kPa).
Chronic hepatitis C, liver cirrhosis, treatment, simeprevir, sofosbuvir.